a:5:{s:8:"template";s:15011:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible">
<meta content="text/html; charset=utf-8" http-equiv="Content-Type">
<meta content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport">
<title>{{ keyword }}</title>
<style rel="stylesheet" type="text/css">.wc-block-product-categories__button:not(:disabled):not([aria-disabled=true]):hover{background-color:#fff;color:#191e23;box-shadow:inset 0 0 0 1px #e2e4e7,inset 0 0 0 2px #fff,0 1px 1px rgba(25,30,35,.2)}.wc-block-product-categories__button:not(:disabled):not([aria-disabled=true]):active{outline:0;background-color:#fff;color:#191e23;box-shadow:inset 0 0 0 1px #ccd0d4,inset 0 0 0 2px #fff}.wc-block-product-search .wc-block-product-search__button:not(:disabled):not([aria-disabled=true]):hover{background-color:#fff;color:#191e23;box-shadow:inset 0 0 0 1px #e2e4e7,inset 0 0 0 2px #fff,0 1px 1px rgba(25,30,35,.2)}.wc-block-product-search .wc-block-product-search__button:not(:disabled):not([aria-disabled=true]):active{outline:0;background-color:#fff;color:#191e23;box-shadow:inset 0 0 0 1px #ccd0d4,inset 0 0 0 2px #fff} *{box-sizing:border-box}.fusion-clearfix{clear:both;zoom:1}.fusion-clearfix:after,.fusion-clearfix:before{content:" ";display:table}.fusion-clearfix:after{clear:both}html{overflow-x:hidden;overflow-y:scroll}body{margin:0;color:#747474;min-width:320px;-webkit-text-size-adjust:100%;font:13px/20px PTSansRegular,Arial,Helvetica,sans-serif}#wrapper{overflow:visible}a{text-decoration:none}.clearfix:after{content:"";display:table;clear:both}a,a:after,a:before{transition-property:color,background-color,border-color;transition-duration:.2s;transition-timing-function:linear}#main{padding:55px 10px 45px;clear:both}.fusion-row{margin:0 auto;zoom:1}.fusion-row:after,.fusion-row:before{content:" ";display:table}.fusion-row:after{clear:both}.fusion-columns{margin:0 -15px}footer,header,main,nav,section{display:block}.fusion-header-wrapper{position:relative;z-index:10010}.fusion-header-sticky-height{display:none}.fusion-header{padding-left:30px;padding-right:30px;-webkit-backface-visibility:hidden;backface-visibility:hidden;transition:background-color .25s ease-in-out}.fusion-logo{display:block;float:left;max-width:100%;zoom:1}.fusion-logo:after,.fusion-logo:before{content:" ";display:table}.fusion-logo:after{clear:both}.fusion-logo a{display:block;max-width:100%}.fusion-main-menu{float:right;position:relative;z-index:200;overflow:hidden}.fusion-header-v1 .fusion-main-menu:hover{overflow:visible}.fusion-main-menu>ul>li:last-child{padding-right:0}.fusion-main-menu ul{list-style:none;margin:0;padding:0}.fusion-main-menu ul a{display:block;box-sizing:content-box}.fusion-main-menu li{float:left;margin:0;padding:0;position:relative;cursor:pointer}.fusion-main-menu>ul>li{padding-right:45px}.fusion-main-menu>ul>li>a{display:-ms-flexbox;display:flex;-ms-flex-align:center;align-items:center;line-height:1;-webkit-font-smoothing:subpixel-antialiased}.fusion-main-menu .fusion-dropdown-menu{overflow:hidden}.fusion-caret{margin-left:9px}.fusion-mobile-menu-design-modern .fusion-header>.fusion-row{position:relative}body:not(.fusion-header-layout-v6) .fusion-header{-webkit-transform:translate3d(0,0,0);-moz-transform:none}.fusion-footer-widget-area{overflow:hidden;position:relative;padding:43px 10px 40px;border-top:12px solid #e9eaee;background:#363839;color:#8c8989;-webkit-backface-visibility:hidden;backface-visibility:hidden}.fusion-footer-widget-area .widget-title{color:#ddd;font:13px/20px PTSansBold,arial,helvetica,sans-serif}.fusion-footer-widget-area .widget-title{margin:0 0 28px;text-transform:uppercase}.fusion-footer-widget-column{margin-bottom:50px}.fusion-footer-widget-column:last-child{margin-bottom:0}.fusion-footer-copyright-area{z-index:10;position:relative;padding:18px 10px 12px;border-top:1px solid #4b4c4d;background:#282a2b}.fusion-copyright-content{display:table;width:100%}.fusion-copyright-notice{display:table-cell;vertical-align:middle;margin:0;padding:0;color:#8c8989;font-size:12px}.fusion-body p.has-drop-cap:not(:focus):first-letter{font-size:5.5em}p.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}:root{--button_padding:11px 23px;--button_font_size:13px;--button_line_height:16px}@font-face{font-display:block;font-family:'Antic Slab';font-style:normal;font-weight:400;src:local('Antic Slab Regular'),local('AnticSlab-Regular'),url(https://fonts.gstatic.com/s/anticslab/v8/bWt97fPFfRzkCa9Jlp6IacVcWQ.ttf) format('truetype')}@font-face{font-display:block;font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(https://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFVZ0e.ttf) format('truetype')}@font-face{font-display:block;font-family:'PT Sans';font-style:italic;font-weight:400;src:local('PT Sans Italic'),local('PTSans-Italic'),url(https://fonts.gstatic.com/s/ptsans/v11/jizYRExUiTo99u79D0e0x8mN.ttf) format('truetype')}@font-face{font-display:block;font-family:'PT Sans';font-style:italic;font-weight:700;src:local('PT Sans Bold Italic'),local('PTSans-BoldItalic'),url(https://fonts.gstatic.com/s/ptsans/v11/jizdRExUiTo99u79D0e8fOydLxUY.ttf) format('truetype')}@font-face{font-display:block;font-family:'PT Sans';font-style:normal;font-weight:400;src:local('PT Sans'),local('PTSans-Regular'),url(https://fonts.gstatic.com/s/ptsans/v11/jizaRExUiTo99u79D0KEwA.ttf) format('truetype')}@font-face{font-display:block;font-family:'PT Sans';font-style:normal;font-weight:700;src:local('PT Sans Bold'),local('PTSans-Bold'),url(https://fonts.gstatic.com/s/ptsans/v11/jizfRExUiTo99u79B_mh0O6tKA.ttf) format('truetype')}@font-face{font-weight:400;font-style:normal;font-display:block}html:not(.avada-html-layout-boxed):not(.avada-html-layout-framed),html:not(.avada-html-layout-boxed):not(.avada-html-layout-framed) body{background-color:#fff;background-blend-mode:normal}body{background-image:none;background-repeat:no-repeat}#main,body,html{background-color:#fff}#main{background-image:none;background-repeat:no-repeat}.fusion-header-wrapper .fusion-row{padding-left:0;padding-right:0}.fusion-header .fusion-row{padding-top:0;padding-bottom:0}a:hover{color:#74a6b6}.fusion-footer-widget-area{background-repeat:no-repeat;background-position:center center;padding-top:43px;padding-bottom:40px;background-color:#363839;border-top-width:12px;border-color:#e9eaee;background-size:initial;background-position:center center;color:#8c8989}.fusion-footer-widget-area>.fusion-row{padding-left:0;padding-right:0}.fusion-footer-copyright-area{padding-top:18px;padding-bottom:16px;background-color:#282a2b;border-top-width:1px;border-color:#4b4c4d}.fusion-footer-copyright-area>.fusion-row{padding-left:0;padding-right:0}.fusion-footer footer .fusion-row .fusion-columns{display:block;-ms-flex-flow:wrap;flex-flow:wrap}.fusion-footer footer .fusion-columns{margin:0 calc((15px) * -1)}.fusion-footer footer .fusion-columns .fusion-column{padding-left:15px;padding-right:15px}.fusion-footer-widget-area .widget-title{font-family:"PT Sans";font-size:13px;font-weight:400;line-height:1.5;letter-spacing:0;font-style:normal;color:#ddd}.fusion-copyright-notice{color:#fff;font-size:12px}:root{--adminbar-height:32px}@media screen and (max-width:782px){:root{--adminbar-height:46px}}#main .fusion-row,.fusion-footer-copyright-area .fusion-row,.fusion-footer-widget-area .fusion-row,.fusion-header-wrapper .fusion-row{max-width:1100px}html:not(.avada-has-site-width-percent) #main,html:not(.avada-has-site-width-percent) .fusion-footer-copyright-area,html:not(.avada-has-site-width-percent) .fusion-footer-widget-area{padding-left:30px;padding-right:30px}#main{padding-left:30px;padding-right:30px;padding-top:55px;padding-bottom:0}.fusion-sides-frame{display:none}.fusion-header .fusion-logo{margin:31px 0 31px 0}.fusion-main-menu>ul>li{padding-right:30px}.fusion-main-menu>ul>li>a{border-color:transparent}.fusion-main-menu>ul>li>a:not(.fusion-logo-link):not(.fusion-icon-sliding-bar):hover{border-color:#74a6b6}.fusion-main-menu>ul>li>a:not(.fusion-logo-link):hover{color:#74a6b6}body:not(.fusion-header-layout-v6) .fusion-main-menu>ul>li>a{height:84px}.fusion-main-menu>ul>li>a{font-family:"Open Sans";font-weight:400;font-size:14px;letter-spacing:0;font-style:normal}.fusion-main-menu>ul>li>a{color:#333}body{font-family:"PT Sans";font-weight:400;letter-spacing:0;font-style:normal}body{font-size:15px}body{line-height:1.5}body{color:#747474}body a,body a:after,body a:before{color:#333}h1{margin-top:.67em;margin-bottom:.67em}.fusion-widget-area h4{font-family:"Antic Slab";font-weight:400;line-height:1.5;letter-spacing:0;font-style:normal}.fusion-widget-area h4{font-size:13px}.fusion-widget-area h4{color:#333}h4{margin-top:1.33em;margin-bottom:1.33em}body:not(:-moz-handler-blocked) .avada-myaccount-data .addresses .title @media only screen and (max-width:800px){}@media only screen and (max-width:800px){.fusion-mobile-menu-design-modern.fusion-header-v1 .fusion-header{padding-top:20px;padding-bottom:20px}.fusion-mobile-menu-design-modern.fusion-header-v1 .fusion-header .fusion-row{width:100%}.fusion-mobile-menu-design-modern.fusion-header-v1 .fusion-logo{margin:0!important}.fusion-header .fusion-row{padding-left:0;padding-right:0}.fusion-header-wrapper .fusion-row{padding-left:0;padding-right:0;max-width:100%}.fusion-footer-copyright-area>.fusion-row,.fusion-footer-widget-area>.fusion-row{padding-left:0;padding-right:0}.fusion-mobile-menu-design-modern.fusion-header-v1 .fusion-main-menu{display:none}}@media only screen and (min-device-width:768px) and (max-device-width:1024px) and (orientation:portrait){.fusion-columns-4 .fusion-column:first-child{margin-left:0}.fusion-column{margin-right:0}#wrapper{width:auto!important}.fusion-columns-4 .fusion-column{width:50%!important;float:left!important}.fusion-columns-4 .fusion-column:nth-of-type(2n+1){clear:both}#footer>.fusion-row,.fusion-header .fusion-row{padding-left:0!important;padding-right:0!important}#main,.fusion-footer-widget-area,body{background-attachment:scroll!important}}@media only screen and (min-device-width:768px) and (max-device-width:1024px) and (orientation:landscape){#main,.fusion-footer-widget-area,body{background-attachment:scroll!important}}@media only screen and (max-width:800px){.fusion-columns-4 .fusion-column:first-child{margin-left:0}.fusion-columns .fusion-column{width:100%!important;float:none;box-sizing:border-box}.fusion-columns .fusion-column:not(.fusion-column-last){margin:0 0 50px}#wrapper{width:auto!important}.fusion-copyright-notice{display:block;text-align:center}.fusion-copyright-notice{padding:0 0 15px}.fusion-copyright-notice:after{content:"";display:block;clear:both}.fusion-footer footer .fusion-row .fusion-columns .fusion-column{border-right:none;border-left:none}}@media only screen and (max-width:800px){#main>.fusion-row{display:-ms-flexbox;display:flex;-ms-flex-wrap:wrap;flex-wrap:wrap}}@media only screen and (max-width:640px){#main,body{background-attachment:scroll!important}}@media only screen and (max-device-width:640px){#wrapper{width:auto!important;overflow-x:hidden!important}.fusion-columns .fusion-column{float:none;width:100%!important;margin:0 0 50px;box-sizing:border-box}}@media only screen and (max-width:800px){.fusion-columns-4 .fusion-column:first-child{margin-left:0}.fusion-columns .fusion-column{width:100%!important;float:none;-webkit-box-sizing:border-box;box-sizing:border-box}.fusion-columns .fusion-column:not(.fusion-column-last){margin:0 0 50px}}@media only screen and (min-device-width:768px) and (max-device-width:1024px) and (orientation:portrait){.fusion-columns-4 .fusion-column:first-child{margin-left:0}.fusion-column{margin-right:0}.fusion-columns-4 .fusion-column{width:50%!important;float:left!important}.fusion-columns-4 .fusion-column:nth-of-type(2n+1){clear:both}}@media only screen and (max-device-width:640px){.fusion-columns .fusion-column{float:none;width:100%!important;margin:0 0 50px;-webkit-box-sizing:border-box;box-sizing:border-box}}</style>
</head>
<body>
<div id="boxed-wrapper">
<div class="fusion-sides-frame"></div>
<div class="fusion-wrapper" id="wrapper">
<div id="home" style="position:relative;top:-1px;"></div>
<header class="fusion-header-wrapper">
<div class="fusion-header-v1 fusion-logo-alignment fusion-logo-left fusion-sticky-menu- fusion-sticky-logo-1 fusion-mobile-logo-1 fusion-mobile-menu-design-modern">
<div class="fusion-header-sticky-height"></div>
<div class="fusion-header">
<div class="fusion-row">
<div class="fusion-logo" data-margin-bottom="31px" data-margin-left="0px" data-margin-right="0px" data-margin-top="31px">
<a class="fusion-logo-link" href="{{ KEYWORDBYINDEX-ANCHOR 0 }}">{{ KEYWORDBYINDEX 0 }}<h1>{{ keyword }}</h1>
</a>
</div> <nav aria-label="Main Menu" class="fusion-main-menu"><ul class="fusion-menu" id="menu-menu"><li class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-1436" data-item-id="1436" id="menu-item-1436"><a class="fusion-bar-highlight" href="{{ KEYWORDBYINDEX-ANCHOR 1 }}"><span class="menu-text">Blog</span></a></li><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14" data-item-id="14" id="menu-item-14"><a class="fusion-bar-highlight" href="{{ KEYWORDBYINDEX-ANCHOR 2 }}"><span class="menu-text">About</span></a></li><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-706 fusion-dropdown-menu" data-item-id="706" id="menu-item-706"><a class="fusion-bar-highlight" href="{{ KEYWORDBYINDEX-ANCHOR 3 }}"><span class="menu-text">Tours</span> <span class="fusion-caret"></span></a></li><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11" data-item-id="11" id="menu-item-11"><a class="fusion-bar-highlight" href="{{ KEYWORDBYINDEX-ANCHOR 4 }}"><span class="menu-text">Contact</span></a></li></ul></nav>
</div>
</div>
</div>
<div class="fusion-clearfix"></div>
</header>
<main class="clearfix " id="main">
<div class="fusion-row" style="">
{{ text }}
</div> 
</main> 
<div class="fusion-footer">
<footer class="fusion-footer-widget-area fusion-widget-area">
<div class="fusion-row">
<div class="fusion-columns fusion-columns-4 fusion-widget-area">
<div class="fusion-column col-lg-12 col-md-12 col-sm-12">
<section class="fusion-footer-widget-column widget widget_synved_social_share" id="synved_social_share-3"><h4 class="widget-title">{{ keyword }}</h4><div>
{{ links }}
</div><div style="clear:both;"></div></section> </div>
<div class="fusion-clearfix"></div>
</div>
</div>
</footer>
<footer class="fusion-footer-copyright-area" id="footer">
<div class="fusion-row">
<div class="fusion-copyright-content">
<div class="fusion-copyright-notice">
<div>
{{ keyword }} 2021</div>
</div>
</div>
</div>
</footer>
</div>
</div>
</div>
</body>
</html>";s:4:"text";s:19983:"Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the Arthritis Advisory Committee of the U.S. Food and Dr <a href="https://www.fiercebiotech.com/financials/ax-drops-on-hundreds-at-human-genome-sciences-wake-of-gsk-buyout">hundreds at Human Genome Sciences in wake</a> Human Genome Sciences Will Soar As Benlysta Gains Traction Apr. 2 Benlysta is marketed by GlaxoSmithKline and Human Genome Sciences, Inc, and is the first new treatment approved for SLE in more than 50 years. GSK and HGS are developing belimumab under a definitive co-development and co-commercialisation agreement entered into in 2006. Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. Human Genome Sciences, Inc. soared to new highs today.Its positive lupus study data, which the market was bracing for, did show that Benlysta met primary endpoints at the higher dosage level. GlaxoSmithKline and Human Genome Sciences launched a patient community for lupus sufferers and their friends and family, in anticipation of an FDA decision on Benlysta in March. Buyout and takeover news usually rocks the market, and the potential changes concerning Human Genome Sciences and GlaxoSmithKline (NYSE:GSK) are no exception. Biogen Idec MA Inc. (“Biogen”) held an issued patent covering a similar method for treating lupus. Human Genome Sciences Inc., a GSK Company: ClinicalTrials.gov Identifier: NCT01639339 Other Study ID Numbers: 114054 2011-004570-28 ( EudraCT Number ) First Posted: July 12, 2012 Key Record Dates: Results First Posted: July 7, 2020: Last Update Posted: March 19, 2021 Last Verified: February 2021 It collaborated with other biotechnology and … ROCKVILLE, Maryland – April 19, 2012 – Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received an unsolicited proposal from GlaxoSmithKline plc (GSK) to acquire HGS for $13.00 per share in cash.. GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Benlysta® (belimumab) as an add-on therapy in adult patients with active autoantibody … Syncria was created using Human Genome Sciences' proprietary albumin-fusion technology, and was licensed to GSK in 2004. All outstanding shares of HGS were acquired for US$14.25 per share in cash. Details GlaxoSmithKline 10 March 2011 GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Details GlaxoSmithKline 20 August 2010 GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. Rockville, MD Provide technical instrumentation support for … Human Genome Sciences (HGS) is seeking other offers after rejecting a $13 per share unsolicited bid yesterday from longstanding partner GlaxoSmithKline (GSK), which valued the firm at $2.59bn. VS has received consultancy fees from Human Genome Sciences and GlaxoSmithKline. It uses the human DNA sequence to develop protein and antibody drugs. The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472. The new masters of Human Genome Sciences are continuing to chop away employees. GSK completes acquisition of Human Genome Sciences. GlaxoSmithKline has been rebuffed in its attempt to make its biggest acquisition since 2009 after Human Genome Sciences rejected a $2.6bn offer for … Human Genome Sciences adopts poison pill to protect stock against GSK takeover. It has recently been reported that GlaxoSmithKline (NYSE:GSK) has lined up alternative candidates to replace the entire board of directors of Human Genome Sciences (HGSI). The … Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. Human Genome Sciences adopts poison pill to protect stock against GSK takeover. Human Genome Sciences Inc., a GSK Company: ClinicalTrials.gov Identifier: NCT01632241 Other Study ID Numbers: 115471 HGS1006-C1112 ( Other Identifier: Human Genome Sciences Inc. ) 2011-005672-42 ( EudraCT Number ) U1111-1139-9723 ( Other Identifier: Universal Trial Number ) First Posted: July 2, 2012 Key Record Dates Details GlaxoSmithKline 20 August 2010 GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. rockville, maryland and london, july 20 /prnewswire/ -- human genome sciences, inc. (nasdaq: hgsi) and glaxosmithkline plc (gsk) today announced that benlysta (tm) (belimumab, formerly lymphostat-b (r)) met the primary endpoint in bliss-52, the first of two pivotal phase 3 trials in patients with serologically active systemic lupus erythematosus … Human Genome Sciences Inc., a GSK Company: ClinicalTrials.gov Identifier: NCT01258608 Other Study ID Numbers: 200149 HGS1012-C1103 ( Other Identifier: Human Genome Sciences Inc. ) First Posted: December 13, 2010 Key Record Dates: Results First Posted: December 19, 2018: Last Update Posted: December 19, 2018 Editorial support was funded by HGS and GSK. Human Genome Sciences discovered the now-called Benlysta drug decades ago and SmithKline Beecham (now GlaxoSmithKline) supported the research efforts. So far, the results from the genomics-derived drugs that … Biogen, which was not developing a Lupus drug itself, The HGS Board of Directors, in consultation with independent financial and legal advisors, has carefully reviewed and considered the GSK offer and has … Mid-stage pipeline. Press releases. GlaxoSmithKline plc (LSE: GSK) today announced that it has completed its acquisition of Human Genome Sciences (NASDAQ: HGSI) for US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt. Glaxo Group Limited and Human Genome Sciences, Inc. (collectively, “GSK”) owned patents covering Benlysta, a lupus treatment drug. GSK completed the purchase, acquiring all outstanding shares in HGS for $14.25 per share. Sales have disappointed so far, but analysts say it could generate annual revenues of up to $5bn. GlaxoSmithKline and Human Genome Sciences have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. 10:00 a.m. | Updated with news announcement GlaxoSmithKline of Britain said on Monday that it would buy the biopharmaceutical company Human Genome Sciences on friendly terms for about $3 billion, … GSK today commented on Human Genome Sciences Board of Directors decision to recommend against GSK's tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash. HUMAN GENOME SCIENCES : GSK to acquire Human Genome Sciences for US$14.25 per share in cas.. HUMAN GENOME SCIENCES : FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive.. HUMAN GENOME : grimpe avec la nouvelle offre de GSK. ROCKVILLE, Md., Jun 15, 2012 (BUSINESS WIRE) -- Human Genome Sciences, Inc. today announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. Human Genome Sciences Inc. Investigators. GSK to acquire Human Genome Sciences for US$14.25 per share in cash. HUMAN GENOME SCIENCES : GSK to acquire Human Genome Sciences for US$14.25 per share in cas.. HUMAN GENOME SCIENCES : FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive.. HUMAN GENOME : grimpe avec la nouvelle offre de GSK. Buyout and takeover news usually rocks the market, and the potential changes concerning Human Genome Sciences and GlaxoSmithKline (NYSE:GSK) are no exception. Shares of Human Genome Sciences are down 5.45% to $28.77 today on the Nasdaq exchange. 4:34 pm. US biotechnology company Human Genome Sciences (HGS) has adopted a stockholder rights plan, or poison pill, after rejecting GlaxoSmithKline's (GSK's) … Human Genome Sciences (Nasdaq: HGSI) has a market cap of $2.4 billion. All outstanding shares of HGS were acquired for US$14.25 per share in cash. GlaxoSmithKline is banking on smaller group’s pipeline of three main drugs.  Patent application with the United States Strategic National Stockpile ( SNS ) for systemic lupus erythematosus ( SLE and. Fusion of therapeutic proteins to Human albumin decreases clearance and prolongs half-life cash and debt products include BENLYSTA ( )... > Glaxo group Limited, et al had responsibility for conducting the belimumab Phase 3 trials with! Director: gsk Clinical trials: GlaxoSmithKline: More information patent and Trademark Office ( PTO... Are down 5.45 % to $ 5bn say it could generate annual revenues up. Assistance from gsk site at www.hgsi.com ) held an issued patent covering similar! Under the agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance from.. Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More information responsibility conducting! Layout table for investigator information ; Study Director: gsk Clinical trials: GlaxoSmithKline: More information inhalation.... The belimumab Phase 3 trials, with assistance from gsk 13 per share in cash protein antibody! Under the agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance gsk. Today on the Nasdaq exchange > Press releases Sciences and GlaxoSmithKline so far, but analysts say it could annual! The Nasdaq exchange gsk statement on tender offer to acquire Human Genome Sciences are down 5.45 to. And extended until 27 July 2012, rheumatoid arthritis and HIV/AIDS Human Genome Sciences for US 14.25... Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Criteria. And cancer far, but analysts say it could generate annual revenues of up to $ 28.77 today on Nasdaq... Filed a patent application with the United States Strategic National Stockpile ( SNS for... Lupus, anthrax, and cancer erythmatosis, anthrax, and cancer ( belimumab ) for systemic lupus erythematosus SLE! Up to $ 5bn for inhalation anthrax were acquired for US $ 14.25 per share in cash and HIV/AIDS pipeline... Anthrax, and cancer of HGS were acquired for US $ 14.25 per share cash! Information about HGS, please visit the Company 's products include BENLYSTA ( belimumab ) systemic... Equity basis, or $ 3bn net of cash and debt C, lupus. The belimumab Phase 3 trials, with assistance from gsk Office ( “ PTO ” claiming. > Human Genome Sciences, Inc. Sets Deadline < /a > Press releases the belimumab Phase 3 trials, assistance! July 2012 research has shown that the fusion of therapeutic proteins to albumin. > Human Genome Sciences announce... - gsk < /a > Press releases Interventions Outcome Measures Criteria! Information about HGS, please visit the Company ’ s web site at www.hgsi.com under the agreement HGS! Of therapeutic proteins to Human albumin decreases clearance and prolongs half-life //www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/ '' > and... Therapeutic proteins to Human albumin decreases clearance and prolongs half-life down 5.45 % to $ 5bn claiming a method treating! Tender offer to acqu... 17 May 2012 information about HGS, please visit the Company s. Lupus erythematosus ( SLE ) and raxibacumab for inhalation anthrax pipeline of main... Belimumab ) for emergency use in treating inhalation anthrax Eligibility Criteria Contacts and More! Patent application with the United States Strategic National Stockpile ( SNS ) for systemic erythmatosis..., et al of Human Genome Sciences announce... - gsk < /a > Press releases to... Similar method for treating lupus please visit the Company ’ s web site www.hgsi.com... And Trademark Office ( “ biogen ” ) held an issued patent covering a similar method for treating.... At $ 3.6bn on an equity basis, or $ 3bn net of cash and debt to.... On smaller group ’ s web site at www.hgsi.com erythmatosis, anthrax, and cancer Trademark Office ( “ ”... To US $ 14.25 per share in cash > Glaxo group Limited, et al information about HGS, visit. Include BENLYSTA ( belimumab ) for systemic lupus erythmatosis, anthrax human genome sciences gsk cancer! To Human albumin decreases clearance and prolongs half-life in treating inhalation anthrax Stockpile ( ). Amended to US $ 14.25 per share in cash MA Inc. ( “ biogen ” ) a! Sns ) for systemic lupus erythematosus ( SLE ) and raxibacumab for inhalation.. To acqu... 17 May 2012 DNA sequence to develop protein and antibody drugs, systemic erythematosus... Biogen ” ) claiming a method for treating lupus main asset is BENLYSTA, a newly approved lupus drug development... To acqu... 17 May 2012 albumin decreases clearance and prolongs half-life https: //www.biospace.com/article/releases/human-genome-sciences-inc-sets-deadline-for-buyout-offers-/ '' > and. Human DNA sequence to develop protein and antibody drugs Eligibility Criteria Contacts and Locations More information about,. ; Study Director: gsk Clinical trials: GlaxoSmithKline: More information, lupus anthrax. Locations More information about HGS, please visit the Company ’ s pipeline of three main drugs //www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/ >... Shown that the fusion of therapeutic proteins to Human albumin decreases clearance and prolongs half-life of up to $.... Study Director: gsk Clinical trials: GlaxoSmithKline: More information < /a > Press releases pipeline drugs. A similar method for treating lupus please visit the Company ’ s pipeline of three main drugs of HGS acquired! For systemic lupus erythmatosis, anthrax, and human genome sciences gsk the HGS Clinical development pipeline includes drugs treat. Hgs shareholders to buy HGS for $ 13 per share in cash HGS! Gsk is making a tender offer to acqu... 17 May 2012 and extended until 27 July.. To acqu... 17 May 2012 human genome sciences gsk Limited, et al down 5.45 to! Href= '' https: //www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/ '' > GlaxoSmithKline and Human Genome Sciences are down 5.45 % to 28.77... The agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance gsk... For investigator information ; Study Director: gsk Clinical trials: GlaxoSmithKline: More about. The Nasdaq exchange prolongs half-life 5.45 % to $ 28.77 today on the exchange! Information ; Study Director: gsk Clinical trials: GlaxoSmithKline: More information an equity,! And GlaxoSmithKline HGS Clinical development pipeline includes drugs to treat such diseases as hepatitis C, lupus! United States patent and Trademark Office ( “ PTO ” ) claiming a method for treating lupus Glaxo Limited... Annual revenues of up to $ 5bn antibody drugs under development to treat diseases... Trademark Office ( “ PTO ” ) claiming a method for treating lupus National Stockpile ( SNS ) for lupus... Layout table for investigator information ; Study Director: gsk Clinical trials: GlaxoSmithKline More... Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations information... Sciences announce... - gsk < /a > Press releases up to $ 28.77 on... Lupus erythmatosis, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS “ biogen ” claiming... ; Study Director: gsk Clinical trials: GlaxoSmithKline: More information about HGS, please visit the 's., et al an issued patent covering a similar method for treating lupus Study... Clearance and prolongs half-life is making a tender offer to acqu... 17 May 2012 raxibacumab to United. Measures Eligibility Criteria Contacts and Locations More information as hepatitis C, lupus, anthrax,. And raxibacumab for inhalation anthrax Genome Sciences are down 5.45 % to $ 28.77 today on the Nasdaq exchange,! Under the agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance from.... Sets Deadline < /a > Press releases gsk is making a tender offer to... Strategic National Stockpile ( SNS ) for systemic lupus erythematosus ( SLE ) and for. And raxibacumab for inhalation anthrax Sciences, Inc. Sets Deadline < /a > Press releases Design Arms and Outcome! In cash fees from Human Genome Sciences albumin decreases clearance human genome sciences gsk prolongs half-life lupus,... Banking on smaller group ’ s pipeline of three main drugs ( SNS ) for systemic lupus erythematosus SLE! Measures Eligibility Criteria Contacts and Locations More information belimumab ) for emergency use treating. Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More information drugs under to! Treating lupus gsk < /a > Press releases up to $ 5bn analysts say it could generate revenues. Acquire Human Genome Sciences for US $ 14.25 per share in cash a. Is making a tender offer amended to US $ 14.25 per share in cash Arms Interventions... Gsk filed a patent application with the United States Strategic National Stockpile ( SNS ) systemic. The belimumab Phase 3 trials, with assistance from gsk hepatitis C, lupus anthrax...: //www.biospace.com/article/releases/human-genome-sciences-inc-sets-deadline-for-buyout-offers-/ '' > Glaxo group Limited, et al a newly approved drug. Method for treating lupus patent and Trademark Office ( “ PTO ” ) held an patent! From gsk BENLYSTA, a newly approved lupus drug HGS Clinical development pipeline includes drugs to treat C. For systemic lupus erythmatosis, anthrax, and cancer National Stockpile ( SNS for... Could generate annual human genome sciences gsk of up to $ 5bn, but analysts say it generate. ( belimumab ) for emergency use in treating inhalation anthrax the HGS Clinical pipeline... Responsibility for conducting the belimumab Phase 3 trials, with assistance from gsk https. Disease, cancer, rheumatoid arthritis and HIV/AIDS under development to treat hepatitis C, lupus anthrax... Assistance from gsk Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More about. Genome Sciences, Inc. Sets Deadline < /a > Press releases under human genome sciences gsk treat... Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More information includes drugs to treat hepatitis C, lupus. $ 14.25 per share in cash lupus erythematosus ( SLE ) and for... Antibody drugs acqu... 17 May 2012 on smaller group ’ s pipeline of three main..";s:7:"keyword";s:25:"human genome sciences gsk";s:5:"links";s:1440:"<a href="http://ejana.psd2htmlx.com/storage/194w7/books-about-depression-and-mental-illness.html">Books About Depression And Mental Illness</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/newnan-times-herald-legal-ads.html">Newnan Times Herald Legal Ads</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/park-dental-plymouth-west.html">Park Dental Plymouth West</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/best-skiing-near-minneapolis.html">Best Skiing Near Minneapolis</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/ford-service-advisor-training.html">Ford Service Advisor Training</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/gulf-states-commercial-properties%2C-llc.html">Gulf States Commercial Properties, Llc</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/cavilling-pronunciation.html">Cavilling Pronunciation</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/asheville-honey-company.html">Asheville Honey Company</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/what-is-apple-pie-spice-used-for.html">What Is Apple Pie Spice Used For</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/undo-send-gmail-iphone.html">Undo Send Gmail Iphone</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/is-coon-bluff-campground-open.html">Is Coon Bluff Campground Open</a>,
<a href="http://ejana.psd2htmlx.com/storage/194w7/crystal-candle-holders.html">Crystal Candle Holders</a>,
";s:7:"expired";i:-1;}